Related Experiment Video
Updated: Jun 28, 2025

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Epigenetic regulation of FOXI2 promotes clear cell renal cell carcinoma progression
Shuai Zhou1,2, Cong Cheng1,2, Yi Xiang Liao1,2
1Department of Urology, Jing Zhou Hospital Affiliated to Yangtze University, PR China.
Abstract:
In recent decades, substantial advancements in epigenetics have unveiled a profound understanding of its mechanisms in tumorigenesis and have offered promising strategies for epigenetic therapy in cancer patients. In our study, through bioinformatics analysis, we discovered a significant downregulation and hypermethylation of FOXI2 in clear cell renal cell carcinoma (ccRCC), while the expression in chromophobe cell carcinoma (chRCC) exhibited the opposite trend. Moreover, we established a strong correlation between FOXI2 expression levels and the prognosis of ccRCC. Gene enrichment analysis and cell function experiments unequivocally demonstrate that FOXI2 possesses the capability to induce cell cycle arrest and inhibit cell proliferation. Our research findings demonstrate that the expression of FOXI2 in ccRCC is under the regulation of promoter hypermethylation. Furthermore, in vitro experiments have conclusively shown that the overexpression of FOXI2 induces cell cycle arrest and inhibits cell proliferation.
Insights
FOXI2 is downregulated and hypermethylated in clear cell renal cell carcinoma (ccRCC), inhibiting cancer cell proliferation. Its overexpression induces cell cycle arrest, offering potential epigenetic therapy strategies for ccRCC.
Area of Science:
- Epigenetics
- Oncology
- Molecular Biology
Background:
- Epigenetic alterations are crucial in tumorigenesis, offering therapeutic targets.
- FOXI2, a transcription factor, has roles in development and disease, but its function in renal cell carcinoma is not well understood.
Purpose of the Study:
- To investigate the role of FOXI2 in clear cell renal cell carcinoma (ccRCC) and chromophobe cell carcinoma (chRCC).
- To explore the potential of FOXI2 as a prognostic marker and therapeutic target in ccRCC.
Main Methods:
- Bioinformatics analysis of gene expression and methylation data.
- Correlation analysis between FOXI2 levels and patient prognosis.
- Gene enrichment analysis and in vitro cell function experiments (cell cycle, proliferation).
Main Results:
- FOXI2 is significantly downregulated and hypermethylated in ccRCC, contrasting with chRCC.
- FOXI2 expression correlates with better prognosis in ccRCC patients.
- FOXI2 induces cell cycle arrest and inhibits cell proliferation in ccRCC cells.
- Promoter hypermethylation regulates FOXI2 expression in ccRCC.
Conclusions:
- FOXI2 acts as a tumor suppressor in ccRCC, with its downregulation driven by promoter hypermethylation.
- FOXI2 warrants further investigation as a potential biomarker and therapeutic target for ccRCC.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
Related Concept Videos
Epigenetic Regulation
X-chromosome...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Master Transcription Regulators
Inheritance of Chromatin Structures
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...